Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/29937
Title: | Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. | Austin Authors: | Wang, Mengzhao;Yang, James Chih-Hsin;Mitchell, Paul L R ;Fang, Jian;Camidge, D Ross;Nian, Weiqi;Chiu, Chao-Hua;Zhou, Jianying;Zhao, Yanqiu;Su, Wu-Chou;Yang, Tsung-Ying;Zhu, Viola W;Millward, Michael;Fan, Yun;Huang, Wen-Tsung;Cheng, Ying;Jiang, Liyan;Brungs, Daniel;Bazhenova, Lyudmila;Lee, Chee Khoon;Gao, Bo;Xu, Yan;Hsu, Wei-Hsun;Zheng, Li;Janne, Pasi A | Affiliation: | Austin Health Westmead Hospital, Australia Sir Charles Gairdner Hospital, Perth, WA, Australia Medical Day Care Centre, Australia Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China University of Sydney, Sydney, New South Wales, Australia National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan Peking University Cancer Hospital and Institute, Beijing, China University of Colorado Cancer Center, Aurora, Colorado, United States Chongqing University Cancer Hospital, chongqing, China Taipei Veterans General Hospital, Taipei, Taiwan First Affiliated Hospital Zhejiang University, Hangzhou, China Affiliated Cancer Hospital of Zhengzhou University, China National Cheng Kung University Hospital, Tainan, Taiwan National Yang Ming University, Taipei, Taiwan, Taiwan University of California, Irvine, Orange, CA, United States Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China ChiMei medical center, liouying, Tainan, Taiwan Jilin Provincial Cancer Hospital, Changchun, China Shanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China UC San Diego Moores Cancer Center, La Jolla, CA, United States Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China National Taiwan University Hospital, Taipei, Taiwan Dizal pharmaceuticals, Shanghai, China Dana-Farber Cancer Institute, Boston, Massachusetts, United States |
Issue Date: | 6-Jul-2022 | Date: | 2022 | Publication information: | Cancer Discovery 2022; 12(7): 1676-1689 | Abstract: | Epidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to lack of effective therapy, the prognosis of these patients was poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible and selective EGFR tyrosine kinase inhibitor, showing activity against EGFR exon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase 1 clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFR exon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response (DoR) has not been reached. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/29937 | DOI: | 10.1158/2159-8290.CD-21-1615 | ORCID: | 0000-0002-9313-3253 0000-0001-8764-4359 0000-0003-2955-9820 0000-0002-2832-2664 0000-0003-0036-1271 0000-0002-7821-4928 |
Journal: | Cancer Discovery | PubMed URL: | 35404393 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/35404393/ | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.